

Friday, 26 November 2021

- 08:45 – 09:00 Welcome and introduction**
Medical oncologist - Aristotelis Bamias, Athens (GR)
Radiation oncologist - Peter Hoskin, Northwood and Manchester (GB)
Urologist - Arnulf Stenzl, Tübingen (DE)
- 09:00 - 10:30 Prostate cancer staging in 2021: Where are we, where are we going? (plenary 1)**
Chairs: Radiologist – Raymond Oyen, Leuven (BE)
Radiation oncologist - Michael Pinkawa, Bonn (DE)
Urologist – Philip Cornford, Liverpool (GB)
- 09:00 - 09:10 State of the Art lecture: Strengths and limitations of PSMA PET for primary staging**
Nuclear medicine physician - Stefano Fanti, Bologna (IT)
- 09:10 - 09:30 Should PSMA PET impact on treatment in newly diagnosed PCa (debate yes vs no)?**
Yes: Urologist - Tobias Maurer, Hamburg (DE)
No: Urologist - Jochen Walz, Marseille (FR)
- 09:30 - 09:40 Optimal staging approach in men recurring after primary treatment**
Urologist - Declan Murphy, Melbourne (AU)
- 09:40 - 09:50 How to use imaging for treatment monitoring in metastatic prostate cancer**
Radiologist – Tavernaraki Ekaterini, Athens (GR)
- 09:50 - 10:00 Summary and evidence based recommendations**
Urologist - Philip Cornford, Liverpool (GB)
- 10:00 - 10:30 Discussion**
- 10.30 - 11.00 Coffee break and e-poster viewing**
- 11:00 - 12:45 Prostate cancer : multi-disciplinary case discussions from local to systemic disease (plenary 2)**
Chairs: Radiation oncologist - Pierre Blanchard, Villejuif (FR)
Urologist - Steven Joniau, Leuven (BE)
- 11:00 - 11:35 Multidisciplinary case discussion: Active surveillance**
Moderator and Case presenter: Urologist - Tobias Maurer, Hamburg (DE)
Case discussants: Pathologist - Eva Compérat, Paris (FR)
Urologist - Veeru Kasivisvanathan, London (GB)
Urologist - Juan Gomez Rivas, Madrid (ES)
- 11:35 - 12:10 Multidisciplinary case discussion: Oligo recurrent disease**
Moderator and Case presenter: Urologist - Alberto Briganti, Milan (IT)
Case discussants: Internal medicine – Stefano Fanti, Bologna (IT)
Radiation oncologist - Pierre Blanchard, Villejuif (FR)
Urologist - Steven Joniau, Leuven (BE)
- 12:10 - 12:45 Multidisciplinary case discussion: Newly diagnosed Hormone sensitive metastatic PCa**
Moderator and Case presenter: Medical oncologist - Oraianthi Fiste, Athens (GR)
Case discussants: Urologist - Axel Merseburger, Lübeck (DE)
Radiation oncologist - Stephanie Kroeze, Zurich (CH)
- 12:45 - 14:00 Lunch break and e-poster viewing**
- 13:00 - 14:00 Lunch Industry session**
- 14:00 - 15:20 Bladder cancer: Bladder preserving strategies in NMIBC (plenary 3)**
Chairs: Urologist - Morgan Rouprêt, Paris (FR)

Urologist - Urologist - Axel Merseburger, Lübeck (DE)
Medical oncologist - Ronald de Wit, Rotterdam (NL)

- 14:00 - 14:10** **Use of bio markers in bladder preserving strategies**
Urologist - Paolo Gontero, Turin (IT)
- 14:10 - 14:20** **Innovative approaches for patients who fail after BCG**
Urologist - Gianluca Giannarini, Udine (IT)
- 14:20 - 14:30** **BCG or more?**
Urologist - Marco Moschini, Lucerne (CH)
- 14:30 - 14:40** **How to improve topical therapy**
Urologist - Fred Witjes, Nijmegen (NL)
- 14:40 - 14:50** **Quality of TURBT**
Urologist - Athanasios Papatsoris, Athens (GR)
- 14:50 - 15:10** **Discussion**
- 15:10 – 15:40** **Coffee break and e-poster viewing**
- 15:40 - 16:00** **EAU Research Foundation session**
Chairs Urologist – Anders Bjartell, Malmö (SW)
 Epidemiologist - Wim Witjes, Arnhem (NL)
- 15:40 – 15:50** **Update on the Prostate Imaging using MRI +/- contrast Enhancement (PRIME) study**
Urologist - Veeru Kasivisvanathan, London (GB)
- 15:50 – 16:00** **Establishment of Patient-Derived Tumor Xenografts to test personalized treatment strategies**
Urologist - Maarten Albersen, Leuven (BE)
- 16:00 - 17:30** **Kidney cancer: Multidisciplinary case discussions (plenary 4)**
Panel: Radiologist – Raymond Oyen, Leuven (BE)
 Pathologist - Antonio Lopez-Beltran, Lisbon (PT)
 Urologist - Axel Bex, London (GB)
 Urologist - Alessandro Volpe, Novara (IT)
 Medical oncologist - Laurence Albiges, Villejuif (FR)
- 16:00 - 16:30** **Multidisciplinary case discussion: Oligometastatic disease**
Case presenter: Urologist - Riccardo Bertolo, Torino (IT)
Moderator: Medical oncologist - Laurence Albiges, Villejuif (FR)
Case discussants: same as panel
- 16:30 - 17:00** **Multidisciplinary case discussion: When not to do partial nephrectomy**
Case presenter: Urologist - Alessandro Larcher, Milan (IT)
Moderator: Urologist - Axel Bex, London (GB)
Case discussants: same as panel
- 17:00 - 17:30** **Multidisciplinary case discussion: Alternative treatment modalities for small renal masses**
Case presenter: Urologist - Carmen Mir, Barcelona (ES)
Moderator: Urologist - Alessandro Volpe, Novara (IT)
Case discussants: same as panel

Saturday, 27 November 2021

- 08:45 - 10:30** **New trials update (plenary 5)**
Chairs: Urologist - Marco Moschini, Lucerne (CH)
 Radiation oncologist - Gert De Meerleer, Leuven (BE)
- 08:45 - 09:00** **NIMBUS trial - follow up**
Speaker: Urologist - Marc-Oliver Grimm, Jena (DE)
Discussant: Urologist - Axel Merseburger, Lübeck (DE)
- 09:00 - 09:15** **Flame trial**
Speaker: Radiation oncologist - Linda Kerkmeijer, Nijmegen (NL)
Discussant: Radiotherapist - Bradley Pieters, Amsterdam (NL)
- 09:15 - 09:30** **IMvigor130**
Speaker: Medical oncologist - Aristotelis Bamias, Athens (GR)
Discussant: Medical oncologist - Thomas Powles, London (GB)
- 09:30 - 09:45** **Extended vs limited Pelvic Lymph node dissection in prostate cancer**
Speaker: Urologist - Jean Lestingi, Marco Leite (BR)
Discussant: Urologist – Ganesh Palapattu, Ann Arbor (US)
- 09:45- 10:00** **CLEAR trial**
Speaker: Urologist - Jens Bedke, Tübingen (DE)
Discussant: Medical oncologist - Laurence Albiges, Villejuif (FR)
- 10:00 - 10:30** **Discussion**
- 10:30 - 11:00** **Coffee break and e-poster viewing**
- 11:00 - 11:50** **Multidisciplinary case discussions – Testis (plenary 6)**
Panel: Radiation oncologist - Peter Hoskin, Northwood (GB)
 Medical oncologist - Jan Oldenburg, Oslo (NO)
 Urologist - Christian Fankhauser, Lucerne (CH)
 Pathologist - Maurizio Colecchia, Milan (IT)
- 11:00 - 11:25** **Multidisciplinary case discussion: Active surveillance**
Case presenter: Medical oncologist - Stefanie Fischer, St. Gallen (CH)
Case discussants: same as panel
- 11:25 - 11:50** **Multidisciplinary case discussion: Poor prognosis or refractory**
Case presenter: Medical Oncologist - Roubini Zakopoulou, Athens (GR)
Case discussants: Same as panel
- 11:50 - 12:05** **Announcement 3 best abstract posters**
Chairs: Radiation oncologist - Ananya Choudhury, Manchester (GB)
 Urologist - Juan Gomez Rivas, Madrid (ES)
 Medical oncologist - Stefanie Fischer, St. Gallen (CH)
- P005 - PSMA-PET- and mpMRI-guided focal radiation dose escalation in primary prostate cancer patients – a planned safety analysis of a two-armed prospective phase II trial (HypoFocal)**
Simon Spohn, Freiburg (DE)
- P047 - Metastasis-free survival after salvage radiotherapy for post-operative prostate cancer patients in the PSMA PET/CT era – a multicenter analysis**
Constantinos Zamboglou, Freiburg (DE)
- P079 - Patient-reported pain by baseline pain status in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1**
Arnulf Stenzl, Tübingen (DE)

- 12:05 - 12:45 Oral presentation of the 6 best abstracts**
 Chairs: Radiation oncologist - Piet Ost, Ghent (BE)
 Urologist - Marco Moschini, Lucerne (CH)
- O1 - External validation and addition of PSMA-PET to the most frequently used nomograms for the ff7 prediction of pelvic lymph-node metastases: An international multicenter study**
 Dennie Meijer, Amsterdam (NL)
- O2 - Reproducibility of tumor staging depends on the applied PSMA-radiotracer - A retrospective analysis on the interobserver variability of PSMA-PET/CT**
 Marinus Jan Hagens, Amsterdam (NL)
- O3 - Health-Related Quality of Life (HRQoL) in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1**
 Arnulf Stenzl, Tübingen (DE)
- O5 - Updated Overall Survival (OS) with atezolizumab (atezo) monotherapy vs. chemotherapy in untreated locally advanced or metastatic Urothelial Carcinoma (mUC) in the Phase III IMvigor130 study**
 Aristotelis Bamias, Athens (GR)
- O6 - Treatment of EAU intermediate risk category non-muscle invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations. A subgroup analysis of the 'NIMBUS' phase III clinical trial**
 Marc-Oliver Grimm, Jena (DE)
- 12:45 - 14:00 Lunch break and e-poster viewing**
13:00 - 14:00 Industry session
- 14:00 - 15:30 Combining immunotherapy with local treatment of GU cancer (plenary 7)**
 Chairs: Medical oncologist - Maria De Santis, Berlin (DE)
 Medical oncologist - Julia Murray, London (GB)
 Urologist - Morgan Rouprêt, Paris (FR)
- 14:00 - 14:15 Understanding checkpoint inhibition to improve patient outcome**
 ina
- 14:15 - 14:25 Immunotherapy and SBRT**
 Radiation oncologist - Stephanie Kroeze, Zurich (CH)
- 14:25 - 14:35 Peri operative immunotherapy in MIBC**
 Medical oncologist - Andrea Necchi, Milan (IT)
- 14:35 - 14.45 Radio-immunotherapy for bladder preservation**
 Radiation oncologist - Ananya Choudhury, Manchester (GB)
- 14.45 - 14.55 The role of surgery in the era of immunotherapy**
 Urologist - Arnulf Stenzl, Tübingen (DE)
- 14.55 - 15.30 Case based discussion**
 Case presenter and moderator: Medical oncologist - Maria De Santis, Berlin (DE)
- 15:30 - 16:00 Coffee break and e-poster viewing**
- 16:00 - 17:00 Personalised approaches in GU cancers (plenary 8)**
 Chairs: Pathologist - Antonio Lopez-Beltran, Lisbon (PT)
- 16:00 - 16:10 Circulating tumour DNA for decision making in high risk and metastatic bladder cancer**
 Researcher - Lars Dyrskjöt, Aarhus (DK)
- 16:10 - 16:20 Practical considerations for genetic testing in prostate cancer**
 Medical oncologist - Elena Castro, Malaga (ES)
- 16:20 – 16:30 The new WHO classification of kidney tumours**

Pathologist - Maria Rosaria Raspollini, Florence (IT)

16:30 – 16:40 **PET/CT: which tracer for which patient?**

Radiologist - Francesco Ceci, Milan (IT)

16:40 - 17:00 **Discussion**

Sunday, 28 November 2021

08:45 - 10:45 **Management of recurrent prostate cancer (plenary 9)**

Chairs: Radiation oncologist - Michael Pinkawa, Bonn (DE)
Medical oncologist - Karim Fizazi, Villejuif (FR)
Urologist - Hein Van Poppel, Leuven (BE)

08:45 - 09:10 **Salvage radiotherapy: increasing dose and use of ADT?**

Case presentation: Radiation oncologist - Charlien Berghen, Leuven (BE)
Yes: Radiation oncologist - Gert De Meerleer, Leuven (BE) (5 min)
No: Urologist - Athanasios Dellis, Athens (GR)
Rebuttal 3 min each (6 min)
Conclusion: Urologist - Hein Van Poppel, Leuven (BE)

09:10 - 09:35 **Local management of radio recurrent disease**

Case presentation: Radiation oncologist - Stephanie Kroeze, Zurich (CH) (4 min)
Surgery: Urologist - Axel Heidenreich, Cologne (DE)
Focal therapy: Rafael Sanchez Salas, Paris (FR) (5 min)
Rebuttal: 3 min each (6 min)
Conclusion: Urologist - Hein Van Poppel, Leuven (BE) (5 min)

09:35 - 10:00 **Metastases directed therapy for a recurrent disease, yes or no? debate**

Case presentation: Urologist – Nicola Fossati, Milan (IT) (4 min)
Pro: Radiation oncologist - Thomas Zilli, Geneva (CH) (5 min)
Con: Urologist – Ganesh Palapattu, Ann Arbor (US)
Rebuttal : 3 min each (6 min)
Conclusion: Radiation oncologist - Michael Pinkawa, Bonn (DE) (5 min)

10:00 - 10:25 **Hormone sensitive recurrent disease: How much systemic treatment is necessary?**

Case presentation: Urologist - Christian Fankhauser, Lucerne (CH)
ADT and any combination: Medical oncologist - Chris Sweeney, Boston (US) (5 min)
ADT: Urologist - Bertrand Tombal, Brussels (BE) (5 min)
Rebuttal : 3 min each (6 min)
Conclusion: Medical oncologist - Karim Fizazi, Villejuif (FR) (5 min)

10:25 - 10:50 **Second line CRPC : Peptide Radioligand Therapy vs second line systemic treatment**

Case presentation: Medical oncologist – Michail Lontos, Athens (GR) (4 min)
Pro: Medical oncologist - Ignacio Duran, Madrid (ES) (5 min)
Con: Urologist - Urologist - Philip Cornford, Liverpool (GB)
Rebuttal : 3 min each (6 min)
Conclusion: Radiation oncologist - Michael Pinkawa, Bonn (DE) (5 min)

10:50 - 11:05 **Announcement 3 best abstract posters**

Chairs: Urologist - Axel Merseburger, Lübeck (DE)
Radiation oncologist - Michael Pinkawa, Bonn (DE)

P094 - Adjuvant immunotherapy versus tyrosine kinase inhibitors in patients with high-risk renal cell carcinoma: A systematic review and network meta-analysis of oncologic and toxicity outcomes

Ekaterina Laukhtina, Vienna (AT)

P154 - Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for non-metastatic urothelial carcinoma of the bladder

Ekaterina Laukhtina, Vienna (AT)

P138 - Overall survival of patients receiving cisplatin or carboplatin for primary metastatic urothelial carcinoma of the bladder: A contemporary Dutch nationwide cohort study

Anke Richters, Nijmegen (NL)

11:05 - 11:55 Take home messages

11:05 - 11:15 Pathologist - Maurizio Colecchia, Milan (IT)
11:15 - 11:25 Radiation oncologist - Michael Pinkawa, Bonn (DE)
11:25 - 11:35 Urologist - Axel Merseburger, Lübeck (DE)
11:35 - 11:45 Radiologist - Raymond Oyen, Leuven (BE)
11:45 - 11:55 Medical oncologist – Jan Oldenburg, Oslo (NO)

11:55 - 12:00 Closing remarks

Medical oncologist - Aristotelis Bamias, Athens (GR)
Radiation oncologist - Peter Hoskin, Northwood and Manchester (GB)
Urologist - Arnulf Stenzl, Tübingen (DE)